Pfizer (PFE) Other financing activities (2009 - 2026)

Pfizer has disclosed Other financing activities across 18 years of filings, most recently posting -$284.0 million for Q1 2026.

• In Q1 2026, Other financing activities rose 20.22% year-over-year to -$284.0 million; the TTM figure through Mar 2026 stood at -$386.0 million (up 69.37% YoY), while the FY2025 annual figure was -$458.0 million, up 2.35% from the prior year.
• Other financing activities fell to -$284.0 million in Q1 2026, from -$43.0 million in the prior quarter.
• Over the last five years, Other financing activities for PFE reached as high as $154.0 million in Q3 2022 and fell as low as -$501.0 million in Q2 2022.
• The 5-year median for Other financing activities is -$140.0 million (2023), against an average of -$197.7 million.
• Annual changes were most pronounced in 2024 — Other financing activities sank 1129.73% — and 2025, when it surged 91.65%.
• A 5-year view of Other financing activities shows it stood at -$342.0 million in 2022, then surged by 94.74% to -$18.0 million in 2023, then sank by 2427.78% to -$455.0 million in 2024, then jumped by 90.55% to -$43.0 million in 2025, then sank by 560.47% to -$284.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered -$284.0 million, -$43.0 million, and -$38.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.